Syed Ehtisham Abidi

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.